CellaVision AB, a pharmaceutical company based in Sweden, specializes in providing digital solutions for blood and body fluid analysis using innovative technology like digital image analysis, artificial intelligence, and information technology. With a low-risk ESG score of 14.8, CellaVision serves customers in hospital laboratories and commercial labs across North America, Europe, China, and Japan. The company's product portfolio includes CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software, generating revenue primarily from analyzer/software sales.